Reported 3 days ago
Regeneron Pharmaceuticals, Inc. (REGN) is highlighted as one of eleven blue chip stocks to consider as it reaches 52-week lows amid a market correction influenced by economic uncertainties. Despite recent declines, the company maintains strong fundamentals, particularly with its Dupixent drug showing promise for expansion into new treatments. Financial strength allows Regeneron to continue investing in a robust R&D pipeline, which may yield significant growth opportunities.
Source: YAHOO